1. Home
  2. BBW vs RIGL Comparison

BBW vs RIGL Comparison

Compare BBW & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Build-A-Bear Workshop Inc.

BBW

Build-A-Bear Workshop Inc.

HOLD

Current Price

$38.19

Market Cap

492.5M

ML Signal

HOLD

Logo Rigel Pharmaceuticals Inc.

RIGL

Rigel Pharmaceuticals Inc.

HOLD

Current Price

$26.07

Market Cap

564.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBW
RIGL
Founded
1997
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
492.5M
564.7M
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
BBW
RIGL
Price
$38.19
$26.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
3
Target Price
$67.71
$45.67
AVG Volume (30 Days)
289.9K
336.0K
Earning Date
05-28-2026
05-05-2026
Dividend Yield
2.51%
N/A
EPS Growth
5.00
1867.68
EPS
3.99
0.44
Revenue
$357,866,000.00
$294,282,000.00
Revenue This Year
$5.63
N/A
Revenue Next Year
$4.62
$12.75
P/E Ratio
$9.37
$59.34
Revenue Growth
N/A
64.15
52 Week Low
$35.38
$17.67
52 Week High
$75.77
$52.24

Technical Indicators

Market Signals
Indicator
BBW
RIGL
Relative Strength Index (RSI) 49.70 31.86
Support Level $35.71 $24.84
Resistance Level $40.16 $31.26
Average True Range (ATR) 1.43 1.42
MACD 0.23 -0.55
Stochastic Oscillator 61.01 5.13

Price Performance

Historical Comparison
BBW
RIGL

About BBW Build-A-Bear Workshop Inc.

Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Share on Social Networks: